Analyst consensus rating
Sarepta Therapeutics Analyst Rating: Hold
SRPT is rated Hold by 23 analysts with a $22.09 target. As of 2026-08-24.
Direct answer
Sarepta Therapeutics's consensus rating is Hold.
23 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $22.09.
Forecast evidence checked August 24, 2026.
Get free Sarepta Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $18.13
- Average price target
- $22.09
- High price target
- $38.00
- Low price target
- $5.00
- Low target gap
- -72.4%
- Target upside
- +21.8%
- High target gap
- +109.6%
- Target range width
- 182%
- Consensus rating
- Hold
- Analysts
- 23
- Evidence date
- August 24, 2026
- Valid through
- August 31, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Sarepta Therapeutics?
Sarepta Therapeutics has a verified Hold consensus. The same dataset has an average price target of $22.09.
How far are Sarepta Therapeutics's low and high targets from the recorded price?
The low target implies -72.4%, while the high target implies +109.6%.
How many analysts are included in Sarepta Therapeutics's consensus?
The verified consensus includes 23 analysts.
How is Sarepta Therapeutics's target upside or downside calculated?
The average target of $22.09 is divided by the recorded price of $18.13, then one is subtracted to produce +21.8%. This does not guarantee a future return.
When was Sarepta Therapeutics's analyst forecast verified?
The data was verified on 2026-08-24. The dataset is valid through 2026-08-31.